HIGHLIGHTS
- who: Manish M. Sood from the Department of Nephrology, The Ottawa Hospital, Ottawa, ON, Canada, Postgraduate Medicine, University of Ottawa have published the research: The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD, in the Journal: (JOURNAL)
- what: This study provides promising evidence that empagliflozin may have CI benefits over other diabetes treatments .
SUMMARY
Cognitive impairment (CI) is the loss of brain functions including concentration, attention, executive function, verbal fluency, and memory beyond what is expected for age. By CKD III, it is estimated that up to 20% of patients have . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.